BPC-157 + TB-500 10+10mg

What is BPC-157 + TB-500 ?

BPC-157 + TB-500 10+10mg is the larger pre-blended vial: 10mg of each peptide, 20mg in total, as lyophilised powder under batch UKPL-9514. The chemistry and the mass ratio match the 5+5mg vial.

BPC-157 is the 15-residue peptide GEPPPGKPADDAGLV at 1419.53 g/mol. TB-500 is listed with the identifiers of thymosin beta 4: CAS 77591-33-4 and 4963.4 g/mol. Their mechanisms and literature are covered on the single BPC-157 and TB-500 pages. Doubling both masses leaves the molar ratio unchanged. No controlled study has tested this combination.

BPC-157 + TB-500 Research Applications

• BPC-157 : VEGFR2 upregulation in endothelial cells (Hsieh et al., 2017) and more FAK and paxillin phosphorylation in tendon fibroblasts (Chang et al., 2011).
• Thymosin beta 4 : integrin-linked kinase and Akt activation in mouse cardiac models (Bock-Marquette et al., Nature, 2004). Its seven-residue actin-binding sequence, LKKTETQ, promoted dermal repair in diabetic and aged mice (Philp et al., 2003).
• Human evidence : only three pilot studies of BPC-157 and no large-scale trials (McGuire et al., Curr Rev Musculoskelet Med, 2025).

The 10+10mg vial suits preclinical soft-tissue and cell-migration designs that use more peptide than a 5+5mg vial supplies. Examples are long explant or co-culture experiments, concentration-response matrices, and studies that must hold one batch across every arm.

10+10mg vs 5+5mg: What the Rung Changes

Nothing chemical changes between the two sizes. Both are equal by mass and about 3.5 to 1 by moles in favour of BPC-157. What changes is procedure. The 10+10mg vial gives twice the peptide per reconstitution, so a study needing a given total mass uses half the vials and crosses one batch boundary instead of two. It supports double the concentration at a fixed fill volume, or double the volume at a fixed concentration. The cost is that 20mg shares one in-use window, which wastes material in slow, low-throughput designs.

Research Overview

BPC-157 + TB-500 10+10mg is a co-formulated research vial holding 10mg of each peptide, 20mg of total peptide, supplied as lyophilised powder. BPC-157 is the pentadecapeptide Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val, CAS 137525-51-0, molecular weight 1419.53 g/mol. TB-500 is the synthetic 17-23 fragment of thymosin beta-4, Ac-Leu-Lys-Lys-Thr-Glu-Thr-Gln, CAS 77591-33-4, molecular weight 4963.4 g/mol. Both compounds sit among the most referenced peptides in cell migration, angiogenesis and tissue repair research, and their individual literatures are covered in full on the separate BPC-157 and TB-500 product pages.

The two components report through distinct mechanisms. For BPC-157, Hsieh and colleagues (J Mol Med, 2017) reported upregulation and internalisation of VEGFR2 in human endothelial cells, and Chang and colleagues (J Appl Physiol, 2011) reported increased phosphorylation of focal adhesion kinase and paxillin in cultured rat tendon fibroblasts. For thymosin beta-4, Bock-Marquette and colleagues (Nature, 2004) reported cell migration and survival effects in mouse cardiac injury models, and Philp and colleagues (Wound Repair Regen, 2003) found the synthetic actin-binding domain peptide LKKTETQ promoted dermal wound repair in diabetic and aged mice.

This is the higher-mass presentation of the blend also offered at 5+5mg, and the chemistry is identical; what changes is quantity. Doubling the mass doubles the molar amounts without altering the ratio: 10mg of BPC-157 is roughly 7.0 µmol and 10mg of TB-500 roughly 2.0 µmol, an approximate 3.5 to 1 molar ratio in favour of BPC-157, exactly as in the 5+5mg rung. The 10+10mg vial means fewer vials, fewer reconstitution events and fewer lot boundaries for a given total mass, at the cost of placing 20mg behind a single in-use window.

No controlled study has evaluated this specific combination, so combination-specific claims cannot be supported, and a 2025 review by McGuire and colleagues (Curr Rev Musculoskelet Med) found no adequately powered randomised controlled trials for BPC-157 in musculoskeletal healing. It is not a licensed medicine and is not for human consumption.

Storage and Reconstitution

Keep sealed vials at -20°C, away from light and moisture. After reconstitution, keep the solution at 2-8°C and use it within 4 weeks, or freeze single-use aliquots at -20°C. With 20mg behind one reconstitution date, aliquot early and avoid repeated freeze-thaw cycles.

Vials are sold on their own, without bacteriostatic water for mixing or other supplies.

How to reconstitute and handle

Treat the vial as one 20mg preparation, with the fill volume set by the concentration your protocol needs. Let the vial and the bacteriostatic water reach room temperature and swab both stoppers. Add the water slowly down the inside wall and swirl gently. Do not shake or vortex. The larger cake can take a little longer to dissolve, so wait for a fully clear, colourless solution. The peptides cannot be separated afterwards. Label the vial with fill volume, concentration and date.

• The two components cannot be separated after reconstitution, and the shorter of the two in-use windows governs the whole preparation. Express the preparation in molar terms only if the 3.5 to 1 asymmetry is accounted for.
• Handle under aseptic laboratory conditions with sterile equipment, prepare single-use aliquots for longer storage, and avoid repeated freeze-thaw cycles.

For the full method, see the peptide reconstitution guide and the reconstitution calculator.

Research References

• Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med, 2017)
• The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang et al., J Appl Physiol, 2011)
• Thymosin beta4 activates integrin-linked kinase and promotes cardiac cell migration, survival and cardiac repair (Bock-Marquette et al., Nature, 2004)
• Thymosin beta 4 and a synthetic peptide containing its actin-binding domain promote dermal wound repair in db/db diabetic mice and in aged mice (Philp et al., Wound Repair Regen, 2003)
• Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (McGuire et al., Curr Rev Musculoskelet Med, 2025)

Published research on BPC-157 + TB-500 is indexed on PubMed. See our full UK buyer's guide for Wolverine Stack and UK buyer's guide for BPC-157 + TB-500 10+10mg.